Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
306 people get GNMK articles and Market Currents by email alert.
Get email alerts on GNMK »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Biotech IPO: GenMark DiagnosticsSA Editor Mohit Manghnani • Wed, May 26, 2010
To learn more about Seeking Alpha Pro, click here.
-
-
-
3 Healthcare Stocks With Minimal Debt, Predicted For GrowthZetaKap • Thu, Oct 25, 2012 -
-
-
5 Low-Debt Healthcare Stocks Positioned For GrowthZetaKap • Thu, Aug 23, 2012
-
-
-
Pharmaceutical And Biotechnology Insider Buys Last WeekGutone • Mon, Jul 2, 2012 -
-
-
-
-
10 Rallying Small-Caps Bought Up By InsidersKapitall • Fri, Sep 16, 2011
-
-
-
Mostly IPO Treats This HalloweenIPO Candy • Fri, Nov 5, 2010
-
A Look at the IPO PipelineIPO Candy • Thu, Jul 1, 2010
-
Market Turmoil Creates Slow Week for Biotech DealsThe Burrill Report • Sun, Jun 6, 2010 -
3 IPOs Planned for This WeekRenaissance Capital IPO Research • Tue, May 25, 2010
-
Business Wire (Mon, 4:05PM)
-
Business Wire (Jun 5, 2013)
-
Business Wire (Jun 4, 2013)
-
Business Wire (Jun 3, 2013)
-
Business Wire (May 10, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Jan 4, 2013)
-
Business Wire (Nov 26, 2012)
-
Business Wire (Nov 20, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Oct 26, 2012)
-
Business Wire (Sep 12, 2012)
-
Business Wire (Aug 15, 2012)
-
Business Wire (Aug 7, 2012)
-
Business Wire (Aug 2, 2012)
GNMK vs. ETF Alternatives
Company Description
"We are a molecular diagnostics company, or a company which detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients, focused on developing and commercializing our eSensor detection technology. Our proprietary electrochemical technology enables fast,... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, June 18, 3:21 PM J.P. Morgan isn't giving up on GenMark Diagnostics (GNMK -12.2%) despite the shares' ~35% decline since June 10. Analyst Tycho Peterson acknowledges the company's tepid guidance, but maintains an Overweight rating on the stock. PT lowered to $15 from $17. Comment! [Healthcare, On the Move]
-
Monday, June 17, 5:30 PM
After-hours top gainers, as of 5:15 p.m.: NSU +4%. URI +4%. TMHC +4%. COCO +3%. HA +3%.
After-hours top losers: GNMK -6%. LOPE -6%. SFL -6%. STAA -4%. BLDR -3%. Comment! [On the Move] - Monday, June 17, 4:53 PM GenMark Diagnostics (GNMK) falls 6.5% AH on top of 8.35% during the regular session. The company says it now sees FY13 revenue of ~$30M versus the $35M it originally estimated. GNMK cites "additional uncertainties relating to the future revenue contribution from its largest customer" (previous). Comment! [Healthcare, On the Move]
-
Tuesday, June 11, 12:45 PM
Midday top 10 gainers: SGOC +56%. BEAT +53%. UQM +30%. PGNX +26%. DOLE +21%. NOA +21%. QCOR +20%. VNDA +19%. ALTI +13%. CMGE +13%.
Midday top 10 Losers: GNMK -23%. LULU -17%. SMA -16%. ALVR -15%. LDK -10%. PRIS -10%. RSOL -10%. IMUC -9%. ECTE -9%. COCO -9%. 1 Comment [On the Move] - Tuesday, June 11, 12:41 PM Shares of GenMark Diagnostics (GNMK -25%) get slammed after one of its customers, Natural Molecular Testing, launches their laboratory developed comprehensive Personalized Medicine Panel using Luminex's (LMNX +6%) xMAP technology. Terms of the multi-year collaboration and license agreement were not disclosed. Comment! [Healthcare, On the Move]
- Wednesday, May 8, 4:47 PM GenMark Diagnostics (GNMK): Q1 EPS of -$0.13 beats by $0.04. Revenue of $11.1M beats by $1.57M. Shares -1.3% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Sunday, April 14, 10:43 PM The rest of the top 25 June additions to the Russell 2000 expected by Credit Suisse: GNMK, AVIV, FBC, TTS, UNXL, GARS, REMY, BNCN, CBK, VRNG, LFVN, GTN, NLS, ENT, AMRI, POWR, DCO, INSM, CUTR, PPBI. "Very few of the bigger adds are owned by actively managed small cap funds," notes CS. Comment! [Quick Ideas]
-
Friday, January 4, 5:50 PM
After-hours top gainers, as of 5:15 p.m.: OPTR +16%. GTI +9%. DSLV +3%. EGLE +2%. GNMK +2%.
After-hours top losers: MSPD -8%. CFFN -5%. G -4%. PL -4%. WCRX -2%. Comment! [On the Move] - Wednesday, June 20, 2012, 1:46 PM Medical diagnostic testing systems provider GenMark Diagnostics (GNMK -3.2%) recovers somewhat after dropping over 9% earlier this morning on the announcement of a 10M share secondary offering. Comment! [Healthcare, On the Move]
- Tuesday, June 12, 2012, 12:00 PM GenMark Diagnostics (GNMK) +6.6% after it raises its Q2 revenue guidance to $3.2M-$3.6M and says it expects to exceed $15M in the full year vs. a prior prediction of $10M. That's above consensus of $2.4M for Q2 and $12M for the year. (PR) Comment! [On the Move, Healthcare]
- Friday, June 17, 2011, 3:46 PM GenMark Diagnostics (GNMK +42%) soars on heavy volume after pricing its 7.07M share secondary offering at $4.25, slightly below Thursday's close. The deal was heavily over-subscribed and removes an overhang that has been pressuring the stock for the past week. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 1 replies
-
FortSumter: I saw somewhere you mentioned $TTS. Do you have a current opinion? I like the analogy to $LL. Not much out there for dd.
-
Joshua Hayes
Big Wave Trading Portfolio Update And Top Current Holdings http://bit.ly/X5RmN4 $CSU $HEES $CAMP $FLT $GNMK $POWR $EAC $HIMX - View all 0 replies
-
- View all 0 replies
-
ZetaKap
3 Healthcare Stocks With Minimal Debt, Predicted For Growth http://bit.ly/XZUOtY $BMTI $CPIX $GNMK @ZetaKap - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
FortSumter: I saw somewhere you mentioned $TTS. Do you have a current opinion? I like the analogy to $LL. Not much out there for dd.